Synthetic Biologics appoints new senior VP of commercial strategy
Barrett was formerly the assistant vice president of established products at Pfizer and the vice president global business manager of infectious diseases at Wyeth Pharmaceuticals. Barrett's expertise in development, commercialization and launch of product candidates to fight infectious diseases will be helpful for the development of SYN-004, a candidate to treat Clostridium difficile infections.
"We are pleased to welcome Lew to the Synthetic Biologics' team and expect that his extensive experience in the development and commercialization of anti-infectives will be vital to the company as we develop SYN-004 for the prevention of C. difficile infections and monoclonal antibody therapies for the treatment of pertussis and Acinetobacter infections," Jeffrey Riley, the CEO of Synthetic Biologics, said.
SYN-004 is an oral enzyme developed for the prevention of C. difficile infections. During his 25-year career at Wyeth, Barrett helped to build the brand and led worldwide commercialization efforts for Zosyn/Tazocin, an in-line intravenous antibiotic, and Tygacil, a broad-spectrum IV antibiotic.
"We recently initiated the manufacturing process for our lead infectious disease candidate, SYN-004, intended to prevent the devastating effects of C. difficile infections, for which there is currently no vaccine or other approved preventive therapy," Riley said. "We look forward to benefiting from Lew's knowledge and big pharma experience for our C. difficile program as well as the other programs in our infectious disease pipeline."
Synthetic Biologics is a biotechnology company that develops biologics for the treatment and prevention of serious infectious diseases.